Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient

Completed

• Conditions: Asthma
• Interventions: Other: 1; Other: 2

• Registration Number: NCT01085474
• Lead Sponsor: AstraZeneca

Brief Summary

Measurement of disease control, treatment adherence and patient knowledge of his/her medication in patients that are receiving a pharmaceutical intervention compared with those patients who receive regular pharmaceutical care.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-03-11
• Study First Submitted QC: 2010-03-11
• Study First Posted: 2010-03-12
• Study Start: 2010-04
• Primary Completion: 2011-07
• Study Completion: 2011-07
• Status Verified: 2013-01
• Last Update Submitted: 2013-01-25
• Last Update Posted: 2013-01-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 384

Inclusion Criteria

• Patients who have given their informed consent and expressed interest in participating in the study
• Asthmatic Patients

Exclusion Criteria

• Patients with communication difficulties.
• Persons who obtain symbicort but not for their own use.
• Patients with other major diseases: Heart problems, COPD, EMPHYSEMA, lung cancer, AIDS.
• Patients with a respiratory infection.
• Patients with seasonal asthma.
• Pregnant women
• Patients who have previously participated in a health education study in asthma.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
1	1	1. Pilot Study: 60 patients (all in the intervention group) 30 patients with intervention A and 30 patients with B intervention)
2	2	Main Study: 600 patients (30 pharmacies control group and 30 pharmacies intervention group, 10 patients per pharmacy)

Primary Outcome Measures

Name	Time	Method
Evaluate the effect of the pharmaceutical intervention on the disease control, treatment adherence and patient knowledge of his/her medication using the MEF, treatment adherence and patient knowledge of the medication indicators.	First a Pilot in 3 months and then the final study in 6 months

Secondary Outcome Measures

Name	Time	Method
Compare disease control in patients who know their medication and those who doesn't.	First a Pilot in 3 months and then the final study in 6 months
Compare disease control in patients who comply with their medication with those who doesn't.	First a Pilot in 3 months and then the final study in 6 months

Trial Locations

Locations (2)

Malaga; 🇪🇸 Malaga, Spain

Research Site; 🇪🇸 Madrid, Spain